A dissertation submitted to the Faculty of Medicine, University of the Witwatersrand, in partial fulfilment of the requirements for the degree Master of Medicine (Virology) / This study was undertaken to determine the role of human parvovlrus B19 (B19) in chronic anaemia of HIV infected TB patients. Patlents were selected from an existing databank of 307 patients included in a MRC HIV/TB study. Twenty-nine patients, 15 colnfected with HIV /TB and 14 Infected with TB only, were identified for further evaluation. These patient's era were subjected to serological and DNA detection studies using IgG and IgM ELISA methods and a nested polymerase chain reaction (PCR) assay. The selection of the nested PCR was based on comparative evaluation of a new rapid 99 cycle PCR method recommended for hepatitis B DNA detection and the nested PCR method established for B19. The nested assay was shown to be the more sensitive system in the context of B19 DNA detection. Serological evaluation of these 29 patients suggested that a greater proportion of HIV/TB patients with chronic anaemia had evidence of recent or past exposure to B19 than those not experiencing anaemia. The nested PCR demonstrated the presence of circulating B19 DNA in 2 coinfected individuals with haematological pictures compatible with persistent B19 infection. B19 DNA was also demonstrated in a TB only patient without anaemia; further haematological and serological evidence in this patient suggested recent exposure to B19. The serological and DNA amplification assay results of these 29 patients would suggest a possible role - either causal or co-factorial - for persistent B19 infection in the establishment of chronic anaemia in HIV/TB patients. / Andrew Chakane 2019

A dissertation submitted to the Faculty of Medicine, University of the Witwatersrand, in partial fulfilment of the requirements for the degree Master of Medicine (Virology) / This study was undertaken to determine the role of human parvovirus B19 (B19) in chronic anaemia of HIV infected TB patients. Patlents were selected from an existing databank of 307 patients included ln a MRC HIV/TB study. Twenty-nine patients, 15 colnfected with HIV/TB and 14 Infected with TB only, were identified for further evaluation. These patients' sera were subjected to serological and DNA detection studies using IgG and IgM ELISA methods and a nested polymerase chain reaction (PCR) assay. The selection of the nested PCR was based on comparative evaluation of a new rapid 99 cycle PCR method recommended for hepatitis B DNA detection and the nested PCR method established for B19. The nested assay was shown to be the more sensitive system in the context of B19 DNA detection. Serological evaluation of these 29 patients suggested that a greater proportion of HIV/TB patients with chronic anaemia had evidence of recent or past exposure to B19 than those not experiencing anaemia. The nested PCR demonstrated the presence of circulating B19 DNA in 2 coinfected individuals with haematological pictures compatible with persistent B19 infection. B19 DNA was also demonstrated in a TB only patient without anaemia; further haematological and serological evidence in this patient suggested recent exposure to B19. The serological and DNA amplification assay results of these 29 patients would suggest a possible role - either causal or co-factorial - for persistent B19 infection in the establishment of chronic anaemia in HIV/TB patients. / Andrew Chakane 2019

Reproduction de : Thèse d'exercice : Médecine : Nancy 1 : 2004. / Titre provenant de l'écran-titre.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2006. / Härtill 5 uppsatser.

Memoria para optar al Título Profesional de Médico Veterinario / Fundamentos: Parvovirus B19 (PV-B19) pertenece a la familia Parvoviridae, género Eritrovirus. Es un virus ADN de hebra simple que presenta secuencias palindrómicas en sus extremos. Es muy prevalente en la población general, llegando a detectarse anticuerpos anti PV-B19 en más del 85% de la población geriátrica. Este virus es el agente causal de una amplia gama de manifestaciones clínicas, cuya severidad depende del estado inmunológico y hematológico del hospedero, e incluye el eritema infeccioso, problemas hematológicos y reumatológicos e hidrops fetal, entre otras. Objetivo: Se determinó la presencia de Parvovirus B19 en pacientes con manifestaciones clínicas asociadas a este virus. Materiales y Métodos: Se analizaron 262 muestras de sangre de pacientes provenientes de distintos centros hospitalarios de la Región Metropolitana y del Servicio de Diagnóstico del Programa de Virología, Facultad de Medicina, Universidad de Chile. De estas muestras, 211 fueron analizadas mediante la técnica de ELISA para la pesquisa de IgM anti PV-B19, 244 con PCR anidado (PCR-Nested), para detectar genoma viral y 185 muestras con ambas técnicas. Resultados: De las muestras analizadas mediante la técnica de PCR anidado, se detectó genoma viral en un 25% de éstas y de las muestras analizadas mediante la técnica de ELISA, se localizó IgM anti PV-B19 en un 19%. Considerando sólo las 185 muestras que fueron analizadas con ambas técnicas, se detectó un 31.9% de positividad. En los casos positivos para el virus, las manifestaciones clínicas prevalentes fueron síndrome febril y eritema infeccioso

La etiología de la arteritis de células gigantes (ACG) es desconocida y sus aspectos etiopatogénicos están poco estudiados.Objetivos. 1. Estudiar la presencia de parvovirus B19 y los virus herpes en las arterias temporales positivas y negativas para la ACG. 2. Estudiar la asociación entre la expresión de metaloproteinasa-2 (MMP-2) y 9 (MMP-9) y el resultado de la biopsia de la arteria temporal (BAT), qué células las expresan y su localización. 3. Analizar si la presencia de estas MMP o los virus se relaciona con las alteraciones histológicas y con las variables clínico-epidemiológicas de los pacientes. 4. Conocer cuáles son los factores predictores del resultado de la BAT. Material y métodos. Se incluyeron todas las BAT valorables realizadas de forma consecutiva en el Hospital Universitari Vall d'Hebron por sospecha clínica de ACG entre Enero de 1997 y Marzo del 2002. Como criterios anatomopatológicos se utilizaron los del ACR. La presencia de ADN vírico se determinó mediante reacción en cadena de la polimerasa. Se realizaron nuevas tinciones de hematoxilina-eosina, de fibras elásticas y tricrómicro de Masson. Los macrófagos CD68, la MMP-2 y la MMP-9 se detectaron mediante inmunohistoquímica. De las historias clínicas se obtuvieron datos clínicos y epidemiológicos. Para el ajuste multivariable se utilizó la regresión logística múltiple.Resultados. En el período en estudio se encontraron 147 BAT válidas, 50 (35%) positivas para ACG y 97 (66%) negativas. Se recuperó la historia clínica de 125 pacientes, 46 (36,8%) con BAT (+) y 79 (63,2%) BAT (-). No se encontró presencia de ADN de los virus estudiados en ninguna de las BAT. La MMP-9 se expresaba con más frecuencia en BAT positivas que negativas para ACG (OR=2,93 p=0,005). Para la MMP-2 la diferencia no fue estadísticamente significativa (p=0,08). Ambas MMP se expresaban en macrófagos de la íntima y de la media cercanos a la lámina elástica interna, en células gigantes y en células con apariencia de músculo liso de la media y de la íntima. Le expresión de MMP-2 se relacionó de forma inversa con la afectación exclusiva de la adventicia (p=0,047) y de forma positiva con la fiebre (p=0,025). La MMP-9 se relacionó de forma positiva con: hiperplasia intimal (0,037), degeneración lámina elástica (0,0001), disminución de la luz (0,008), hipercolesterolemia (0,032), hiperestesia craneal (0,009). Ajustando por variables que podrían influir en el resultado de la biopsia, (edad, género, tiempo de evolución de los síntomas hasta la BAT, tratamiento previo con glucocorticoides y año de realización de la biopsia), se mantuvieron los resultados entre la expresión de MMP-2 y MMP-9. El engrosamiento de la arteria temporal, la disminución de su pulso y la pérdida de peso se asociaron de forma independiente con el resultado de la biopsia, ajustando por edad, género, días de evolución, tratamiento previo, año de realización, cefalea, hiperestesia craneal, claudicación mandibular, alteraciones visuales y VSG.Conclusiones. Ninguno de los virus estudiados parece estar implicado en la etiopatogenia de la ACG. La MMP-9, al contrario de la MMP-2, parece tener un papel en dicha etiopatogenia. La MMP-9 se asocia con hipercolesterolemia y la MMP-2 con la fiebre. El engrosamiento, la disminución de la luz de la arteria temporal y la pérdida de peso se han encontrado asociadas a una elevada probabilidad de resultado positivo de la biopsia en los enfermos estudiados. / The etiology of giant cell arteritis (GCA) is unknown and their etiopathogenic aspects have been little studied.Aims. 1. To study the presence of parvovirus B19 and herpes viruses in positive and negative temporal artery biopsies (TAB) for GCA. 2. To study the association between metalloproteinase-2 (MMP-2) and 9 (MMP-9) expression and TAB result, the type of cells expressing them and their location. 3. To analyse if the presence of these MMP or the viruses is related to histologic findings and to clinical-epidemiological variables of the patients. 4. To identify predictive factors of TAB result. Material and methods. All the valid TAB consecutively performed in Hospital Universitari Vall d'Hebron because of clinical suspicion of GCA between January 1997 and March 2002. ACR anatomopathological criteria were used. The presence of viral DNA was determined by means of polymerase chaín reaction. New hematoxilin-eosin, elastic fibers and Masson's trichromic stainings were performed. CD68 macrophages, MMP-2 and MMP-9 were detected by immunohistochemistry. Clinical and epidemiological data were obtained from clinical files. The multiple logistic regression was used for multivariable analysis. Results. During the study period, 147 valid TAB were found, 50 (35%) positive and 97 (66%) negative for GCA. Clinical files of 125 patients were retrieved, 46 (36.8%) with positive TAB and 79 (63.2%) with negative TAB. DNA of the viruses studied was not found in any of the TAB. MMP-9 was more frequently expressed in positive than in negative TAB for GCA (OR=2.93; p=0.005). The difference was not statistically significant for MMP-2 (p=0.08). Both MMP were expressed in macrophages of the intima and the media near internal elastic lamina, in giant cells and in cells of the media and the intima resembling smooth muscle cells. The expression of MMP-2 was inversely related to the isolated involvement of the adventitia (p=0.047) and positively to fever (p=0.025). MMP-9 was positively related to: intimal hyperplasia (0.037), elastic lamina degeneration (0.0001), luminal narrowing (0.008), hypercholesterolemia (0.032), scalp tenderness (0.009). Controlling for variables which could influence the biopsy result (age, gender, evolution of symptoms before TAB, previous glucocorticoids treatment and year of biopsy performance), the results between MMP-2 and MMP-9 expression remained unaltered. Temporal artery thickening, pulse decrease and weight loss were independently associated with biopsy result, controlling for age, gender, days of evolution of symptoms, previous treatment, year of biopsy performance, headache, scalp tenderness, jaw claudication, visual disturbances and erythrocyte sedimentation rate.Conclusions. None of the viruses studied seems to be involved in GCA etiopathogenesis. MMP-9, in contrast to MMP-2, seems to play an etiopathogenic role in GCA. MMP-9 is associated with hypercholesterolemia and MMP-2 with fever. Temporal artery thickening and luminal narrowing and weight loss are associated with a high probability of positive biopsy result in the patients studied.

Background: Persistent anemia has been described in kidney transplant (KTx) recipients with parvovirus B19 virus infection. However, the epidemiology of parvovirus B19 and parvovirus B19-related anemia after KTx remains unclear. We conducted this systematic review (1) to investigate the incidence of parvovirus B19 infection after KTx and (2) to assess the incidence of parvovirus B19 among KTx patients with anemia. Materials and Methods: A systematic review was conducted in EMBASE, MEDLINE, and Cochrane databases from inception to March 2019 to identify studies that reported the incidence rate of parvovirus B19 infection and/or seroprevalence of parvovirus B19 in KTx recipients. Effect estimates from the individual studies were extracted and combined using random-effects, generic inverse variance method of DerSimonian and Laird. The protocol for this systematic review is registered with PROSPERO (no. CRD42019125716). Results: Nineteen observational studies with a total of 2108 KTx patients were enrolled. Overall, the pooled estimated seroprevalence of parvovirus B19 immunoglobulin G was 62.2% (95% confidence interval [CI]: 45.8%-76.1%). The pooled estimated incidence rate of positive parvovirus B19 DNA in the 1st year after KTx was 10.3% (95% CI: 5.5%-18.4%). After sensitivity analysis excluded a study that solely included KTx patients with anemia, the pooled estimated incidence rate of positive parvovirus B19 DNA after KTx was 7.6% (95% CI: 3.7%-15.0%). Among KTx with anemia, the pooled estimated incidence rate of positive parvovirus B19 DNA was 27.4% (95% CI: 16.6%-41.7%). Meta-regression analysis demonstrated no significant correlations between the year of study and the incidence rate of positive parvovirus B19 DNA (P = 0.33). Egger's regression asymmetry test was performed and demonstrated no publication bias in all analyses. Conclusion: The overall estimated incidence of positive parvovirus B19 DNA after KTX is 10.3%. Among KTx with anemia, the incidence rate of positive parvovirus B19 DNA is 27.4%. The incidence of positive parvovirus B19 DNA does not seem to decrease overtime.

Background: Although infectious diseases are less common in high-income countries compared to low-income countries, they should still be seriously considered as a relevant public health issue. Some professions, such as healthcare workers, laboratory workers, and care providers may be at a particularly high risk of acquiring infections. In Germany, work-related infectious diseases are after skin diseases, the most common cause of occupational diseases reported to the Institution for Statutory Social Accident Insurance and Prevention in the Health Care and Welfare Services (BGW). An occupational disease, as defined by the WHO, is “any disease contracted primarily as a result of an exposure to risk factors arising from work activity”, although this definition varies between countries. In order for infections to be recognized as an occupational disease, either the identification of an index case is needed or it must be shown that the likelihood in which a particular case of illness was attributable to the occupation: the probability of causation must be greater than 50% (the “more-likely-than-not” rule). A general “rule-of-thumb” is to equate the probability of causation of 50% with a relative risk of disease equal to two (the “doubling of the risk”). This principle is used by many countries for the recognition of an occupational disease. Few studies have concentrated on the risk of infectious disease in daycare workers, who may be at higher risk than the general population due to their frequent and close contact to young children. Research questions: The primary aim of this review was to summarize the evidence on the relationship between being a daycare worker working with children and the possible increased risk for infections not preventable by vaccines. Furthermore, research gaps were to be identified. Finally, the implications for practice and health policy based on the evidence were to be described. Methods: For the systematic reviews with meta-analysis, the Medline and Embase databases were searched using search strings defined according to the Population, Exposure, Comparison, and Outcomes (PECO) applicable to the research questions in order to find studies on vaccine non-preventable infections in daycare workers published since 2000. The search hits were evaluated using predefined inclusion and exclusion criteria by two independent reviewers. A separate manual search was performed by reviewing the reference lists of key articles and systematic reviews. The “citation tracking factor” by Google scholar was used to find additional relevant studies. The resulting studies were extracted and were assessed in eight risk of bias domains for the judgement of study quality. With a meta-analysis, the pooled risk of infections for daycare workers compared to the general or a reference population was calculated. The quality of evidence was assessed by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Results: After evaluating the 6879 records, ten methodologically adequate studies were identified regarding parvovirus B19 infection (four studies) and cytomegalovirus (CMV) infection (six studies). No adequate studies on other infections were found. For parvovirus B19 infection, three cross-sectional studies and one retrospective cohort study were identified. The pooled parvovirus B19 seroprevalence in daycare workers was 70.3% (95% CI 59.5-80.4). Of three studies investigating the relative risk (RR) of parvovirus B19 infection on daycare workers, only one study evaluated seroconversion rates. There was an indication for an increased risk of parvovirus B19 infection for daycare workers compared to the unexposed population (RR = 1.12, 95% CI 0.98–1.27) using prevalence estimators. Furthermore, daycare workers had a higher parvovirus B19 seroconversion rate compared to the unexposed population (RR = 2.63, 95% CI 1.27–5.45) in the low risk of bias study. For CMV infection, five cross-sectional studies and one cohort study were included. The pooled CMV seroprevalence of daycare workers was 59.3% (95% CI 47.6-70.9). The four studies investigating risk of infection indicated an increased seroprevalence for daycare workers compared to a reference population (prevalence ratio, RR=1.54, 95% CI 1.33-1.77). No study evaluated CMV seroconversions for daycare workers. Conclusions: The findings suggest higher parvovirus B19 and cytomegalovirus seroprevalence for daycare workers compared to the general population. There is a need for longitudinal and higher-quality studies regarding infections not preventable by vaccines in daycare workers, as well as a need to study other infections for which daycare workers may be at higher risk. Nonetheless, when the actual occupational seroconversion risk is considered by taking into account the pre-occupational seroprevalences, the pooled relative risks for both parvovirus B19 and CMV infection are compatible with a doubled seroconversion risk corresponding to a probability of causation due to the occupation of at least 50%. Preventative efforts in the workplace are needed based on the legally required risk assessment at the workplace. Moreover, it is important to raise awareness of the potential risk of infection in women trying to conceive or during pregnancy. Recommendations to prevent infections in the day care center include using gloves and frequent handwashing after exposure to young children’s bodily fluids, cleaning surfaces, and avoiding intimate contact with young children if pregnant, although these measures alone may not completely protect the daycare worker from infection. Currently, in Germany, an employment ban for pregnant daycare workers depends on the federal state. To avoid occupational risks for pregnant daycare workers, scientific-based guidelines should be developed and applied consistently.

Die entzündliche Kardiomyopathie ist eine heterogene Erkrankung. Die häufigste Ursache ist eine Virusinfektion, wobei Parvovirus B19 (B19V) der bedeutendste Erreger ist. In dieser Arbeit wurden potenzielle Therapie für die speziellen klinischen Verläufe und deren Phänotypen untersucht. In vitro konnte gezeigt werden, dass Telbivudin in B19V-infizierten/B19V-non-structural protein-1-stimulierten humanen mikrovaskulären Endothelzellen (HMEC-1) endothelial-protektiv wirkt. In einem klinischen Versuch wurden dann 4 Patienten, bei denen eine aktive Transkription des B19V nachgewiesen wurde, für 6 Monate mit Telbivudin behandelt. Alle Patienten verbesserten sich. Ein anderes klinisches Szenario stellt die schwere Entzündung des Myokards dar, welche gewöhnlich mit einer inaktiven/persistierenden Infektion des B19V verbunden ist. Eine Behandlung mit Immunsuppressiva ist hier umstritten, da eine Reaktivierung des Virus befürchtet wird. Um diesen Aspekt weiter zu untersuchen, würde eine Therapie mit Prednisolon in Kombination mit Azathioprin bei 51 B19V-positiven und 17 B19V-negativen Patienten angewandt. Beide Gruppen profitierten in ähnlichem Maße von der Kombinationstherapie, wobei sich die Virusmenge nicht signifikant veränderte. Bei B19V-negativen Patienten konnte über die Persistenz von CD20+ B-Lymphozyten in den EMBs die Untergruppe der „Steroide non-responder“ klassifiziert werden. Im weiteren Verlauf wurden 6 Patienten mit Rituximab, einem monoklonalen Antikörper, der spezifisch gegen CD20+ B-Lymphozyten gerichtet ist, behandelt. Hiervon zeigten 5 Patienten eine ausgezeichnete klinische Verbesserung. Ein Patient mit Myokarditis-induzierten kardiogenen Schock zeigt, dass die Entlastung des linken Ventrikels mittels eines Mikroaxialpumpensystems zu einer rapiden Abnahme der Entzündungszellen führt. Zusammenfassend liefert diese Arbeit Belege für die Wirksamkeit und die Notwendigkeit einer phänotypbasierten Behandlung bei der entzündlichen Kardiomyopathie. / Inflammatory cardiomyopathy is a heterogenous disease. Viral etiologies are the most common, with parvovirus B19 (B19V) being the most prominent culprit. Currently, no specific treatment for inflammatory cardiomyopathy exists. In this study, tailored treatment strategies were investigated as potential therapies for specific clinical scenarios. The antiviral drug telbivudine was investigated in the setting of EMB-proven B19V-associated inflammatory cardiomyopathy. In cell culture, telbivudine exhibited endothelial-protective effects on B19V-infected/B19V-non-structural protein-1-stimulated human microvascular endothelial cells (HMEC-1). Clinically, four B19V-positive patients improved following six-month telbivudine regimen in a single-patient use approach. The results were translated to the “PreTOPIC” clinical study, for further evaluation in a randomized placebo-controlled setting. In a different clinical scenario, severe myocardial inflammation is usually associated with inactive/persistent B19V. Here, the use of immunosuppression is controversial, fearing viral flare-up. We investigated combined prednisolone/azathioprine therapy in 51 B19V-positive and 17 B19V negative patients in a single-center observational study. Both groups gained similar benefit, while viral loads did not significantly vary. Among virus-negative phenotypes, EMB-proven CD20+ B lymphocyte persistence characterized a subgroup of steroid non-responders. In this cohort, six patients were treated with rituximab, a monoclonal antibody selectively targeting CD20+ B lymphocytes. Five patients showed outstanding clinical improvement parallel to CD20+ B lymphocyte depletion. Lastly, in a single case of myocarditis-induced cardiogenic shock, mechanical left ventricular unloading via axial flow pump proved to exert disease-modifying effects. In conclusion, this thesis provides evidence for the efficacy and need for phenotype-based inflammatory cardiomyopathy treatment.

O eritrovírus humano (parvovírus), gênero Erytrovírus, é o único representante da família Parvoviridae responsável por um amplo espectro de doenças. Estudos recentes têm demonstrado variações entre o eritrovírus e orientam a reclassificação destas variantes em três genótipos distintos: genótipos 1, 2 e 3. O papel do eritrovírus na etiopatogenia de doenças hematológicas em humanos permanece incerto. Este estudo teve como objetivo principal avaliar a relação etiopatogênica dos genótipos do eritrovírus e as citopenias de origem desconhecida. Materiais e Métodos: Participaram do estudo 285 indivíduos procedentes do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Destes, 120 apresentavam citopenias de origem desconhecida (grupo 1 Casos), 45 eram doadores de medula óssea (grupo 2 Controles Saudáveis) e 120 eram pacientes com doenças oncohematológicas crônicas (grupo 3 Controles com Neoplasias Hematológicas). A pesquisa do vírus foi realizada pelo método de semi-nested PCR (Reação em Cadeia da Polimerase) em amostras de medula óssea e de sangue periférico. As fitas complementares foram seqüenciadas diretamente do produto da PCR. Amostras de plasma de todos os indivíduos incluídos no estudo foram testadas para presença de anticorpos IgG e IgM específicos contra o eritrovírus por ensaio imunoenzimático. Resultados: Dos 40 indivíduos com resultado positivo na PCR em amostra da medula óssea, o genótipo 1 foi encontrado em 22 (55%), o genótipo 2 em 5 (12,5%), o genótipo 3 em 13 (32,5%). Quando comparadas as freqüências de positividade entre os casos e controles (Grupo 1 VS Grupos 2 e 3), não encontramos diferença significativa com relação ao genótipo 1 (p=0, 192) nem com relação aos genótipos 2 e 3 (p= 0.143). A soroprevalência encontrada na amostra foi de 71%. Conclusão: Concluímos que a infecção isolada pelo eritrovírus, independente do genótipo encontrado, não tem relação etiopatogênica com as citopenias de origem desconhecida, uma vez que o vírus foi encontrado com a mesma freqüência nos casos e nos controles estudados / The human erythrovirus (parvovirus), genus Erytrovirus, is the only representative of the family Parvoviridae responsible for a broad spectrum of diseases. Recent studies have shown variations within the erythrovirus and guide the classification of these variants in three distinct genotypes: genotypes 1, 2 and 3. The role of the erythrovirus in the etiopathogenesis of hematological diseases in humans remains uncertain. This studys main objective was to evaluate the etiopathogenic relationship between the genotypes of the erythrovirus and the cyptopenias of unknown origins. Methods and Materials: 285 individuals coming from the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo participated in the study. Of these, 120 represented cytopenias of unknown origins (group one Cases), 45 were bone marrow donors (group two - Healthy Controls), and 120 were patients with chronic oncohematological diseases (group three Controls with Hematological Disorder). The research of the virus was done through the semi-nested PCR method (polymerase chain reaction) in bone marrow and peripheral blood samples. The complementary strands were sequenced directly from the product of the PCR. Plasma samples from all of the individuals included in the study were tested through immunosorbent assay for the presence of lgG and IgM antibodies specific to the eritrovírus. Results: Of the 40 individuals that had positive PCR bone marrow results, the genotype 1 was found in 22 (55%), the genotype 2 in 5 (12.5%), and genotype 3 in 13 (32.5%). When the frequency of positivity was compared between the cases and the controls (Group 1 vs. Groups 2 and 3), we did not find a significant difference in relation to genotype 1 (p=0.192), nor did we find a significant difference in relation to genotypes 2 and 3 (p=0.143). The overall seroprevalence found in the samples was 71%. Conclusion: We conclude that the infection isolated by the erytrovirus, independent of the genotype found, does not have a etiopathogenic relationship with the cytopenias of unknown origins, hence the virus was found with the same frequency in the cases and the controls studied